Julie Lepin is Senior Vice President, Head of Regulatory, Safety, and Quality (RSQ) at Sana Biotechnology.

Julie has over 25 years of extensive regulatory experience and leadership, overseeing the development and registration of products across many modalities within the areas of oncology, bone disease, dermatology, and supportive care. Julie joined Sana from Amgen where she was Vice President, Regulatory Affairs for Oncology, leading the regulatory strategies for a diverse and extensive portfolio of clinical stage and marketed products. The most recent approval in her portfolio was Lumykras, the first KRASG12C targeting agent. Prior to Amgen, Julie was Head of Regulatory at Juno Therapeutics, Head of Regulatory, Oncology at Merck, and Head of Regulatory, Intercontinental at Amgen. Her leadership and regulatory insights were instrumental in numerous product approvals including Neulasta, Kepivance, Vectibix, Prolia, Keytruda, and more.

Julie holds a BSc. in Biotechnology and Molecular Biology, and Masters in Ethics and Theology from Kings College London, and Masters in Regulatory Science from the University of Wales.